Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NK521 in the Treatment of Advanced Solid Tumors

NCT07657416 is registered in ClinicalTrials.gov with Base Therapeutics (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07657416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07657416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NK521 in the Treatment of Advanced Solid Tumors
Lead sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
December 31, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc), malignant ascites, ovarian cancer